Skip to main content
Surgical Case Reports
Fig. 3 | Surgical Case Reports

Fig. 3

From: Fatal acquired coagulation factor V deficiency after hepatectomy for advanced hepatocellular carcinoma as a possible immune checkpoint inhibitor-related adverse event: a case report

Fig. 3

Perioperative course. The solid line indicates the change in prothrombin time, while the dotted line indicates change in the activated partial thromboplastin time. Before surgery, 6 courses of atezolizumab (1200 mg) plus bevacizumab (796.5 mg [15 mg/kg]) were administered with 21-day intervals between courses. Right trisegmentectomy of the liver was performed 8 days after completion of atezolizumab and bevacizumab administration. POD postoperative day

Back to article page